← Back to all trials
Not Yet Recruiting
NCT07760155
A Phase 2 Study on the Safety and Efficacy of the Anti-BAFF-R Monoclonal Antibody, ESG206, in Patients With Systemic Lupus Erythematosus
Conditions: Systemic Lupus Erythematosus (SLE)
Sex: All
Ages: 18 Years – 75 Years
Healthy volunteers: No
Phase: PHASE2
Enrollment: 40
Sponsor: Shanghai Escugen Biotechnology Co., Ltd
Location: Shenzhen Third People's Hospital Shenzhen Guangdong
Summary
This is a multicenter, randomized, double-blind, placebo-controlled Phase II study designed to evaluate the efficacy and safety of ESG206 in participants with Systemic Lupus Erythematosus (SLE).
Eligibility Criteria
Inclusion Criteria:
* Adults (≥18 years of age) with a confirmed diagnosis of Systemic Lupus Erythematosus
* Evidence of active disease at screening
* Willing and able to provide written informed consent
Exclusion Criteria:
* Have other autoimmune diseases that may interfere with the assessment of SLE
* Prior or recent use of prohibited immunomodulatory therapies
* Clinically significant infections, malignancies, or uncontrolled medical conditions
* Pregnancy or breastfeeding
Source: ClinicalTrials.gov (NCT07760155). StuddyBuddy aggregates publicly available trial information.
